BioCryst Says Orladeyo On Slow, Steady Ramp To Blockbuster Sales

 
• By Joseph Haas

Company believes its oral HAE prophylaxis will gradually reach the billion-dollar sales threshold, with about 80% of revenue coming from the US market.

Competitive market
BioCryst's Orladeyo is gradually establishing its place in the competitive HAE space • Source: Shutterstock

More from New Products

More from Scrip